» Articles » PMID: 39519817

Synergistic Combination of Quercetin and Mafosfamide in Treatment of Bladder Cancer Cells

Overview
Journal Molecules
Publisher MDPI
Specialty Biology
Date 2024 Nov 9
PMID 39519817
Authors
Affiliations
Soon will be listed here.
Abstract

Bladder cancer, which has a rising incidence, is the 10th most common cancer. The transitional cell carcinoma histotype is aggressive and often current therapies are ineffective. We investigated the anti-proliferative effect of quercetin, a natural flavonoid, in combination with the alkylating agent mafosfamide (MFA) on two human bladder cancer cell lines, namely RT112 and J82, representing the progression from low-grade to high-grade tumors, respectively. In both cell types, the combined treatment led to a synergic reduction in cell viability confirmed by a combination index of less than one, though different biological responses were noted. In J82 cells, MFA alone and, to a lesser extent, with quercetin caused cell cycle arrest in the G2/M phase, but only the combined treatment triggered apoptotic cell death. In contrast, in RT112 cells, quercetin induced autophagy, evidenced by the autophagosome formation and the increase in LC-3 lipidation. Interestingly, the synergistic effect was observed only when cells were pre-treated with MFA for 24 h before adding quercetin, not in the reverse order. This suggests that quercetin may help overcome MFA resistance to apoptosis. Although further studies are needed, investigating the combined effects of quercetin and MFA could help elucidate the mechanisms of drug resistance in bladder cancer treatment.

References
1.
Saha S, Panigrahi D, Patil S, Bhutia S . Autophagy in health and disease: A comprehensive review. Biomed Pharmacother. 2018; 104:485-495. DOI: 10.1016/j.biopha.2018.05.007. View

2.
Meeran S, Katiyar S . Cell cycle control as a basis for cancer chemoprevention through dietary agents. Front Biosci. 2007; 13:2191-202. PMC: 2387048. DOI: 10.2741/2834. View

3.
Moch H, Amin M, Berney D, Comperat E, Gill A, Hartmann A . The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022; 82(5):458-468. DOI: 10.1016/j.eururo.2022.06.016. View

4.
Terao J . Factors modulating bioavailability of quercetin-related flavonoids and the consequences of their vascular function. Biochem Pharmacol. 2017; 139:15-23. DOI: 10.1016/j.bcp.2017.03.021. View

5.
Jiang D, Gupta S, Kitchlu A, Meraz-Munoz A, North S, Alimohamed N . Defining cisplatin eligibility in patients with muscle-invasive bladder cancer. Nat Rev Urol. 2021; 18(2):104-114. DOI: 10.1038/s41585-020-00404-6. View